To find the optimal Primimg dose and side effects associated with Atracurium
Phase 3
Completed
- Conditions
- Health Condition 1: null- All were good at the time of trial
- Registration Number
- CTRI/2018/03/012622
- Lead Sponsor
- Arun Chakravarthi Periyasamy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 90
Inclusion Criteria
ASA 1,2 Patients
Exclusion Criteria
pregnancy patients, ASA 3,4 Patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Priming dose of atracuriumTimepoint: Priming dose of atracurium at the end of 3 minutes side effects were monitored and also PNS started to find out the time of onset of action
- Secondary Outcome Measures
Name Time Method side effects with primingTimepoint: at the end of 3 minutes